Structure Therapeutics (NASDAQ:GPCR) Receives Market Outperform Rating from JMP Securities

JMP Securities reiterated their market outperform rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report report published on Wednesday,Benzinga reports. JMP Securities currently has a $91.00 target price on the stock.

GPCR has been the topic of several other research reports. Morgan Stanley started coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, HC Wainwright began coverage on Structure Therapeutics in a report on Wednesday, December 4th. They set a “buy” rating and a $80.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics presently has an average rating of “Buy” and a consensus price target of $86.50.

Structure Therapeutics Price Performance

Shares of GPCR traded up $1.35 during midday trading on Wednesday, reaching $29.25. The stock had a trading volume of 267,812 shares, compared to its average volume of 792,549. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -39.53 and a beta of -3.41. The company’s fifty day simple moving average is $35.71 and its two-hundred day simple moving average is $39.09. Structure Therapeutics has a 1-year low of $26.23 and a 1-year high of $62.74.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. Sandia Investment Management LP acquired a new position in shares of Structure Therapeutics in the second quarter valued at approximately $39,000. Assetmark Inc. raised its position in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after buying an additional 719 shares during the last quarter. Quarry LP acquired a new stake in shares of Structure Therapeutics in the 2nd quarter worth $79,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after acquiring an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC acquired a new position in shares of Structure Therapeutics during the third quarter worth about $202,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.